It is not the first time that Emergent BioSolutions has gotten into trouble, the Food and Drug Administration has already fined her in different occasions due to similar failures
Photo: Martín Alipaz / EFE
All types of companies require a good reputation and more if they are dedicated to health issues, but the company Emergent BioSolutions , crucial in the vaccine supply chain in Johnson & Johnson’s plan, generates many doubts because he has faced different fines from the federal health authorities.
Emergent BioSolutions, is not very well known but it is key in Johnson & Johnson’s plan to deliver 100 million doses of its coronavirus vaccine in the United States by the end of May.
In the week it was announced that around 15 million doses of the Johnson & Johnson vaccine were spoiled , after workers at the Emergent BioSolutions plant in Baltimore, which makes two coronavirus vaccines, accidentally combined the ingredients.
The batch of vaccines thankfully never left the plant , but in light of this fact, information in the possession of AP emerged that the Food and Drug Administration (FDA) has repeatedly fined Emergent for . with mold and other contaminants in one of its facilities .
The FDA inspected the Baltimore plant in April 2020, precisely when the agreement with J&J was announced. The federal agency then criticized Emergent for problems with his testing of a potential treatment for anthrax, and for lack of training for his staff. in the particular operations carried out as part of their function and in good manufacturing practices.
Johnson & Johnson reported that the batch of vaccines produced by Emergent cannot be used because it does not meet quality standards and assured that will deliver the .
With information from AP and El Financiero
You may also like:
Tea we recommend
